Amgen loses bid for order blocking sandoz copy of neupogen.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      AMGEN Ltd.
    • Abstract:
      Novartis AG can sell in the U.S. the first imitation of a bioengineered drug approved by the Food and Drug Administration, a judge ruled in a setback for Amgen Inc. A federal judge in San Francisco allowed Novartis's Sandoz unit to sell its version of Amgen's $1.2 billion-a-year Neupogen cancer drug. [Extracted from the article]
    • Abstract:
      Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)